McKinley Capital Management’s UroGen Pharma URGN Stock Holding History

McKinley Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,198	Closed	-$44K	–	287
2019 Q1	$44K	Sell	1,198 -17,321	-94%	-$726K	﹤0.01%	244
2018 Q4	$798K	Buy	18,519 +386	+2%	+$17.4K	0.06%	138
2018 Q3	$856K	Sell	18,133 -1,090	-6%	-$50.6K	0.05%	147
2018 Q2	$957K	Buy	19,223 +18,210	+1,798%	+$1.06M	0.06%	139
2018 Q1	$50K	Buy	+1,013	New	+$50.7K	﹤0.01%	304

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

McKinley Capital Management's URGN Position: Q2 2019 in Review

McKinley Capital Management sold out of UroGen Pharma (URGN) in Q2 2019, closing a stake of 1,198 shares — an estimated $44K sold.

McKinley Capital Management first reported a position in URGN in Q1 2018 and held it in 5 quarters. The position peaked at $957K in Q2 2018. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2019.

McKinley Capital Management reported no remaining UroGen Pharma position as of Q2 2019 after selling out during the quarter.
McKinley Capital Management sold 1,198 UroGen Pharma shares in Q2 2019, an estimated $44K.
McKinley Capital Management first reported a position in UroGen Pharma in Q1 2018 and held it in 5 quarters.
McKinley Capital Management's UroGen Pharma position peaked at $957K in Q2 2018.
84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2019.

Based on McKinley Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.